New hope for young bone cancer patients: immunotherapy drug tested in relapse

NCT ID NCT03006848

Completed Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This study tested a drug called avelumab in 19 children and young adults (ages 12 to 49) whose osteosarcoma (a type of bone cancer) had returned or was not responding to standard treatments. The goal was to see if avelumab could shrink tumors or stop the cancer from growing for at least 16 weeks. Researchers also monitored side effects and quality of life. The drug works by helping the immune system attack cancer cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Children's Hospital Los Angeles

Los Angeles, California, 90027, United States
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
St Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States
Texas Children's Cancer Center

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

OSTEOSARCOMA